Product Description
Mechanisms of Action: GDF8 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Puerto Rico, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Obesity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| COURAGE | P2 |
Active, not recruiting |
Obesity |
2026-02-16 |